A small study involving nine patients and nine healthy controls found that ME/CFS patients taking LDN (3.0–5.0 mg/day) have restored TRPM3-like ionic currents in NK cells, which supports the hypothesis that LDN may have potential as a treatment for ME/CFS [181]. The gene discussed is TRPM3; the disease is myalgic encephalomeyelitis/chronic fatigue syndrome.